No Data
No Data
No Data
No Data
No Data
Hyundai Health Technology (00919) subsidiary plans to acquire a Rolls-Royce Dawn V12 Auto for 1.22 million Singapore dollars
Zhitong Financial App News, Modern Health Technology (00919) announced that on February 8, 2024, the buyer Splendid Overseas Pte Limited (an indirect wholly-owned subsidiary of the company) and the seller F1 Autos Pte Limited signed a car sales agreement for the purchase. The cost was SGD 1.22 million. According to reports, the object of the purchase was a Rolls-Royce Dawn V12 Auto. The announcement stated that the purpose of purchasing the car was to enhance the group's reputation by improving the shuttle service
Zhitong FinanceFeb 18 23:38 ET
Hyundai Health Technology (00919)'s purchase of a Rolls-Royce Yaoying vehicle involved approximately HK$7.102 million
Jinwu Financial News | Modern Health Technology (00919) announced that on February 8, 2024, Splendid Overseas Pte Limited, an indirect wholly-owned subsidiary of the company, signed a car sales agreement with the seller for the purchase. The cost was SGD 1.22 million (approximately HK$7.102 million). The object of the purchase was a Rolls-Royce Dawn V12 Auto.
金吾財訊Feb 18 23:30 ET
MODERNHEALTHTEC: Interim Report 2023/24
Futu NewsDec 21, 2023 03:38 ET · Announcements
Modern Healthcare Technology Swings to Loss in Fiscal H1; Shares Up 4%
Modern Healthcare Technology Holdings (HKG:0919) swung to a loss of HK$28.8 million, or HK$0.0318 per share, in the fiscal first half, from a profit of HK$40.7 million, or HK$0.0449 per share, in the
MT NewswiresNov 28, 2023 23:07 ET
Modern Health Technology (00919.HK)'s interim earnings decreased 6.3% year over year to HK$210 million
Gelonghui November 28 | Modern Health Technology (00919.HK) announced that for the six months ended September 30, 2023, the Group's revenue decreased by 6.3% compared to the same period last year to HK$210 million. The net loss was approximately HK$285.69 million, while the net profit for the same period last year was HK$40.96 million. The Group will continue to expand its business at the appropriate time to achieve the goal of long-term value growth and bring the highest return to shareholders. For the period under review, the loss per share was HK3.18 cents, while the profit per share for the same period last year was HK4.49 cents. The board of directors has not approved disbursements for the period ending September 30, 2023 6
Gelonghui FinanceNov 28, 2023 08:59 ET
Hyundai Health Technology (00919) released interim results, losses attributable to shareholders of HK$28.802 million and changed year-on-year profit to loss
Hyundai Health Technology (00919) announced the results for the six months ended September 30, 2023. The group achieved profit...
Zhitong FinanceNov 28, 2023 08:57 ET
No Data
No Data